StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Humalog (insulin lispro) by Quarter

Humalog (insulin lispro) — Worldwide revenue YoY (%) [legacy] (%)

QuarterlyAnnual

Eli Lilly Humalog (insulin lispro): 69.0% in Q4 2024, up 102.0 pts from a year earlier. That is the highest of the 26 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
69.0%
Period ended Dec 31, 2024
Change on a year earlier
+102.0 pts
-33.0% in Q4 2023
History
26 quarters
Since Q1 2018
Sources
26
Documents cited below

Where the Q4 2024 figure comes from

“|| Humalog (b) | 619.9 | 366.6 | 69% | 2,324.8 | 1,663.3 | 40%”

Source: Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedHumalog (insulin lispro) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q4 2024Dec 31, 202469.0%+102.0 ptsEarnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 202435.0%+47.0 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 202443.0%+44.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 202417.0%+42.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023-33.0%-24.0 ptsEarnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-12.0%+17.0 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 2023-1.0%+25.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 2023-25.0%-25.0 ptsForm 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-9.0%+7.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022-29.0%-24.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-26.0%-35.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 20220.0%+11.0 ptsEarnings Release (Form 8-K FY2022Q1 EX-99.1) (filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-16.0%-10.0 ptsEarnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-5.0%-6.0 ptsForm 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 20219.0%+27.0 ptsForm 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-11.0%-6.0 ptsForm 10-Q FY2021Q1 (filed 2021-04-30) ↗

Cite this data

StockData. (2026). Eli Lilly Humalog (insulin lispro) (%), quarterly Q1 2018–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-humalog-yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.